Increased risk of hyperkalaemia w/ aliskiren, K salts, K-sparing diuretics, ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressants, trimethoprim, co-trimoxazole. Increased risk of severe anaphylactoid reactions w/ extracorporeal treatments. Increased risk of angioedema w/ sacubitril/valsartan, racecadotril, mTOR inhibitors (eg, sirolimus, everolimus, temsirolimus), gliptins (eg, linagliptin, saxagliptin, sitagliptin, vildagliptin). Increased risk of angioneurotic oedema w/ estramustine. Increased risk of hyperkalaemia w/ K-sparing diuretics, K salts. Reversible increased serum conc & toxicity of lithium. Lethal ventricular fibrillation & CV collapse w/ verapamil, IV dantrolene. Increased blood-glucose lowering effect w/ antidiabetic medicines (insulins, oral hypoglycaemics). Increased antihypertensive effect w/ baclofen. Excessive BP reduction w/ non-K-sparing diuretics. Attenuated antihypertensive effect w/ NSAIDs eg, acetylsalicylic acid, COX-2 inhibitors, nonselective NSAIDs. Varied amlodipine conc w/ strong CYP3A4 inducers eg, rifampicin, Hypericum perforatum
. Increased amlodipine exposure w/ CYP3A4 inhibitors eg, PIs, azole antifungals, macrolides (eg, erythromycin or clarithromycin), verapamil, diltiazem. Increased risk of hypotension w/ clarithromycin. Increased hypotensive effect w/ antihypertensive agents (eg, β-blockers), vasodilatators. Further BP reduction w/ TCAs, antipsychotics, anaesth. Reduced antihypertensive effect w/ sympathomimetics, corticosteroids, tetracosactide. Increased antihypertensive effect & risk of orthostatic hypotension w/ α-blockers (eg, prazosin, alfuzosin, doxazosin, tamsulosin, terazosin). Potentiated amlodipine antihypertensive effect w/ amifostine. Nitritoid reactions w/ injectable gold (Na aurothiomalate). Increased BP-lowering effects w/ grapefruit or grapefruit juice. Increased tacrolimus blood levels.